News
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...
The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...
There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...
I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...
For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...
Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results